Novartis Gets Boost as Autoimmune Drug Suceeds in Key Trials
Ianalumab showed improvement in disease activity in patients with Sjögren's disease, according to a statement Monday. The drug candidate was well tolerated and demonstrated a favorable safety profile for the disease, which has very limited treatment options.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
‘My husband had cancer and died just three days after our wedding'
A widow whose husband had cancer and died just three days after their wedding has said she believes he "held on" to marry her before "going up to the angels". Dean Dunphy, 33, was diagnosed with stage 4 brain cancer, specifically glioblastoma, in August 2023 after experiencing stroke-like symptoms and muscle twitching - with doctors describing the condition as "an old man's disease". His wife Michaela Dunphy, 31, who worked in admin and lives in Dublin in the Republic of Ireland, said Dean underwent two brain surgeries to remove cancerous tissue, as well as chemotherapy and radiotherapy, but the tumour kept growing.
Bloomberg
38 minutes ago
- Bloomberg
Biogen Sees Potential in Combining Alzheimer's and Obesity Drugs
If Novo Nordisk A/S 's wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer's disease, Biogen Inc.'s Chief Executive Officer Chris Viehbacher doesn't see it as a roadblock for his company's medication. Rather, he sees it as an opportunity to potentially combine drugs and create a more potent therapy. 'As we look out over the next five years, we're probably going to see a treatment much like any other complex disease,' he said in an interview with Bloomberg News, meaning there will be 'different mechanisms of action that you need.'
Bloomberg
an hour ago
- Bloomberg
UK Primary Health Properties Fends Off KKR Bid for Landlord Assura
Primary Health Properties Plc has prevailed in the fiercely contested takeover battle for rival landlord Assura Plc, a watershed deal that saw shareholders reject a cash offer from private equity in favor of remaining invested in a UK public company. The transaction will create the UK's largest publicly traded health care landlord, bringing together PHP's £2.81 billion ($3.8 billion) portfolio with Assura's £3.1 billion of assets to create the country's eighth most valuable real estate investment trust by market capitalization.
